For cancers of the head and neck, Erbitux was investigated in two main studies: • the first study involved 424 patients with locally advanced cancer, looking at the effects of adding Erbitux to radiotherapy; • the second study involved 442 patients with recurrent or metastatic cancer, looking at the effects of adding Erbitux to a platinum-based anticancer medicine combination.